Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuropathy: a cross-sectional cohort study
These findings underscore the importance of inclusion of a range of multimodal CIPN assessments to characterize relative burden of toxicity between chemotherapy agents. CIPN severity was similar between nab-paclitaxel and paclitaxel cohorts, but more severe in oxaliplatin-treated patients.
Authors
- Arun V. Krishnan (ORCID: https://orcid.org/0000-0001-8883-8825)
- Peter Grimison (ORCID: https://orcid.org/0000-0002-2653-1657)
- Hannah C. Timmins (ORCID: https://orcid.org/0000-0001-5504-1625)
- Susanna B. Park (ORCID: https://orcid.org/0000-0003-0218-4707)
- Terry Trinh
- Kimberley Au (ORCID: https://orcid.org/0000-0002-3782-2628)
- Tiffany Li (ORCID: https://orcid.org/0000-0003-1138-1489)
- David Goldstein
Institutions
- The University of Sydney (AU)
- UNSW Sydney (AU)
- Chris O’Brien Lifehouse (AU)
- Prince of Wales Hospital (AU)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-04-15
- DOI
- https://doi.org/10.2340/1651-226x.2025.42935
- Citations
- 3
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Bristol-Myers Squibb
- Cancer Institute NSW
- University of New South Wales
- National Health and Medical Research Council